Endoscopic sclerotherapy of bleeding esophageal varices. A comparative study of results in patients with schistosomiasis and cirrhosis.
Endoscopic sclerotherapy for bleeding esophageal varices was carried out in 78 patients with schistosomiasis (Group I) and 71 cirrhotic patients (Group II). All Group I patients had uniformly good liver function. According to Child's classification 25 patients (35%) of Group II were Child A, 16 (23%) Child B and 30 (42%) Child C. The sclerotherapy was performed by intravascular injections of 3% ethanolamine. Throughout a follow-up period of at least 24 months, hemorrhage recurred in 13% of the Group I patients, with one death (1%). The Child A category had a 24% recurrence with a 4% death rate, Child B a 38% recurrence with a 50% death rate, and Child C group a 73% recurrence with no survivals. A comparison of patients with schistosomiasis and cirrhosis type A revealed no differences with respect to rebleeding or survival (p greater than 0.05). Differences were significant for bleeding recurrence and survival in Child B patients as compared with schistosomiasis patients (p less than 0.025). This difference was highly remarkable when patients with schistosomiasis were compared with Child C cases, both for recurrence and survival (p less than 0.001). On the basis of these observations it is concluded that results of sclerotherapy depend fundamentally on liver function, and thus this procedure is justified in the early phases of liver cirrhosis.
Sakai
P
P
Department of Digestive Endoscopy, Hospital das Clinicas, University of São Paulo Medical School, Brazil.
Boaventura
S
S
Capacci
M L
ML
Macedo
T M
TM
Ishioka
S Z
SZ
D000293:Adolescent; D000328:Adult; D000368:Aged; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy*; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012552:Schistosomiasis / Q000150:complications*; D012597:Sclerosing Solutions / Q000008:administration & dosage*
D012597:Sclerosing Solutions